Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Dr Allan Jordan

Allan joined Sygnature Discovery in February 2019 and is Vice President of Oncology Drug Discovery.

Allan has over 23 years of medicinal chemistry and drug discovery experience with an excellent record of delivering compounds to clinical trials across a variety of therapeutic areas. Allan was previously Principal Scientist at RiboTargets (now Vernalis). Following this, he joined Cancer Research UK (CRUK) as Head of Chemistry in the Manchester Institute Drug Discovery Unit. During his 9 year tenure, he led both internal research activities and national and international research collaborations to deliver novel oncology therapeutics, alongside his responsibilities for synthetic and medicinal chemistry, computational chemistry, informatics and structural biology. He was also passionately involved in science communication and research engagement through direct contact and the broadcast media, engaging in face to face interactions with more than twenty thousand of the charity’s supporters.  In 2016 he was a recipient of a CRUK “Flame of Hope” award (the charity’s highest award for voluntary services) for his contributions to research engagement on behalf of the charity.

Allan has a BSc (Hons.) in Chemistry and a PhD in synthetic organic chemistry from the University of Manchester and undertook post-doctoral research at the University of Reading. He is a frequent speaker on the global events circuit for drug discovery. Visit our events page to see if he is attending any of our upcoming conferences and why not connect with him on LinkedIn ahead of the day?

Latest News

View All

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…

Sygnature Discovery invests £3.75M in Compound Management…

Sygnature Discovery collaborates with Axol Bioscience to…